TABLE 1.
Clinical characteristics
| All (n = 68) | PD‐L1 high (n = 27) | PD‐L1 low (n = 41) | P value | |
|---|---|---|---|---|
| n (%) | n (%) | n (%) | ||
| Age (y), median (range) | 70 (31, 91) | 70 (55, 91) | 71 (31, 85) | .405 |
| Gender | ||||
| Male | 51 (75) | 22 (85) | 29 (71) | .310 |
| Female | 17 (25) | 5 (19) | 12 (29) | |
| Smoking status, n (%) | ||||
| Never | 11 (16) | 2 (7) | 9 (22) | .602 |
| Ex or current | 57 (84) | 25 (93) | 32 (78) | |
| PS | ||||
| 0‐1 | 52 (76) | 23 (85) | 29 (71) | .160 |
| 2 | 16 (24) | 4 (15) | 12 (29) | |
| Histology | ||||
| Squamous cell | 24 (35) | 8 (30) | 16 (39) | .682 |
| Adenocarcinoma | 38 (56) | 16 (59) | 22 (54) | |
| Others | 6 (9) | 3 (11) | 3 (7) | |
| Previous chemotherapy | ||||
| 0 | 26 (38) | 22 (81) | 4 (10) | <.001* |
| 1 | 27 (40) | 3 (11) | 24 (59) | |
| >2 | 15 (22) | 2 (7) | 13 (32) | |
| Treatment | ||||
| Nivolumab | 26 (38) | 2 (7) | 24 (59) | <.001* |
| Pembrolizumab | 33 (49) | 24 (89) | 9 (22) | |
| Atezolizumab | 9 (13) | 1 (4) | 8 (20) | |
| Stage | ||||
| III | 11 (16) | 3 (11) | 8 (20) | .333 |
| IV | 38 (56) | 18 (67) | 20 (49) | |
| Recurrence | 19 (28) | 6 (22) | 13 (32) | |
| PD‐L1 tumor expression | ||||
| High (≥50%) | 27 (40) | 27 (100) | 0 | |
| Low (<50%) | 41 (60) | 0 | 41 (100) | |
| Gene alterations | ||||
| WT | 39 (57) | 18 (67) | 21 (51) | .116 |
| EGFR | 5 (7) | 0 | 5 (12) | |
| ALK | 2 (3) | 1 (4) | 1 (2) | |
| NE | 22 (32) | 8 (30) | 14 (34) | |
Abbreviations: ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; NE, not examined; PD‐L1, programmed death–ligand 1; PS, East Cooperative Oncology Group performance status; WT, wild type.
*
P < .05.